For the past 20 years, CDC vaccine advisers’ approach to HPV vaccination followed a trajectory of expanding eligibility, strengthening uptake and adding new indications. Now, the agency has convened a new workgroup to re-examine the vaccine from the ground up — its effectiveness, dosing, safety and long-term population impact.
